Results 141 to 150 of about 12,211 (152)

Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory Diseases

CNS Neuroscience & Therapeutics, 2007
Olaf Stüve, Jeffrey L. Bennett
exaly  

Progressive multifocal leukoencephalopathy and natalizumab

Journal of Neurology, 2011
Ralf Gold, Kerstin Hellwig
exaly  

Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis

European Journal of Immunology, 2012
Mireia Sospedra, Roland Martin, Raquel Planas   +2 more
exaly  

Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab

Multiple Sclerosis Journal, 2018
Patricia Mulero, Cristina Auger, Mar Tintoré   +2 more
exaly  

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

Multiple Sclerosis Journal, 2016
Lucia Moiola, Bruno Colombo, Vittorio Martinelli   +2 more
exaly  

Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases

Multiple Sclerosis Journal, 2013
Lucia Moiola, Massimo Filippi, Maria Trojano   +2 more
exaly  

Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy

Journal of NeuroVirology, 2017
Luisa Imberti, Cristina Scarpazza, Ruggero Capra   +2 more
exaly  

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

Multiple Sclerosis Journal, 2018
Mike P. Wattjes, Birgit I. Lissenberg-Witte, Theo Rispens   +2 more
exaly  

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

Journal of Neurology, 2013
Patrick Vermersch, Ludwig Kappos, Heinz Wiendl   +2 more
exaly  

A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis

Journal of Clinical Pharmacology, 2016
Tatiana Plavina, Daniel Mikol
exaly